AGEN
Agenus Inc

12,580
Loading...
Loading...
News
all
press releases
Are Options Traders Betting on a Big Move in Agenus tock?
Investors need to pay close attention to AGEN stock based on the movements in the options market lately.
Zacks·9d ago
News Placeholder
More News
News Placeholder
Agenus (AGEN) Reports Q2 Loss, Beats Revenue Estimates
Agenus (AGEN) delivered earnings and revenue surprises of -28.21% and +2.68%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Gilead Sciences (GILD) Tops Q2 Earnings and Revenue Estimates
Gilead (GILD) delivered earnings and revenue surprises of +3.08% and +1.95%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates
AnaptysBio (ANAB) delivered earnings and revenue surprises of +10.67% and +36.82%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
Zacks.com featured highlights include QuantumScape, Civeo and Agenus
QuantumScape, Civeo, and Agenus show sharp earnings acceleration, signaling potential upside before Wall Street catches on.
Zacks·2mo ago
News Placeholder
QuantumScape & 2 Other Stocks to Buy for Earnings Acceleration
QS, CVEO, and AGEN show strong earnings acceleration this month - often a signal of stock price momentum ahead.
Zacks·2mo ago
News Placeholder
Is CVS Health (CVS) Stock Outpacing Its Medical Peers This Year?
Here is how CVS Health (CVS) and Agenus (AGEN) have performed compared to their sector so far this year.
Zacks·2mo ago
News Placeholder
VKTX Stock Down on Wider-Than-Expected Loss in Q2, Nil Sales
Shares of Viking slide after Q2 loss widens to 58 cents per share on rising R&D and nil revenues, missing estimates by 14 cents.
Zacks·2mo ago
News Placeholder
AstraZeneca's AL Amyloidosis Drug Misses Goal in Late-Stage Studies
AZN's anselamimab fails to meet key goals in late-stage AL amyloidosis trials despite signs of subgroup benefit.
Zacks·3mo ago
News Placeholder
MDGL Stock Soars 11% on New Patent Protecting Rezdiffra Dosing Rights
Madrigal Pharmaceuticals stock jumps 11% after securing a new U.S. patent for Rezdiffra's dosing, reinforcing exclusivity through 2044.
Zacks·3mo ago

Latest AGEN News

View

Advertisement|Remove ads.

Advertisement|Remove ads.